Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
CD44 is the principal cell surface receptor for hyaluronate
Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B., & Seed, B. (1990) · Cell · doi:10.1016/0092-8674(90)90694-a · Cited by 2,438
Gene silencing by microRNAs: contributions of translational repression and mRNA decay
Huntzinger, E., & Izaurralde, E. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2936 · Cited by 2,339 · cited 1×
“One single miRNA can target multiple genes due to the imperfect complementarity with target mRNA and simultaneously regulate different signaling pathways, implying that miRNA may potentially play a major regulatory role in coordinating cancerous signaling networks [8].”
BackgroundTransactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010 · cited 1×
“MicroRNA-34a (miR-34a) is a miRNA regulated by the p53 network at transcriptional level and has been shown to be remarkably downregulated in a variety of cancers [10].”
BackgroundThe microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,400
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells
Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., Xiang, D., DeSano, J. T., Bommer, G. T., Fan, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006816 · Cited by 689
Cited by
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Kwak, S.-Y., Lew, T. T. S., Sweeney, C. J., Koman, V. B., Wong, M. H., Bohmert-Tatarev, K., Snell, K. D., Seo, J. S., Chua, N.-H., & Strano, M. S. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0375-4 · Cited by 602
Hyaluronic acid for anticancer drug and nucleic acid delivery
Dosio, F., Arpicco, S., Stella, B., & Fattal, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.011 · Cited by 596
Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting
Garg, U., Chauhan, S., Nagaich, U., & Jain, N. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.023 · Cited by 505
Mir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
Nie, Y., Li, D., Peng, Y., Wang, S., Hu, S., Liu, M., Ding, J., & Zhou, W. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119513 · Cited by 495
MicroRNA delivery through nanoparticles
Lee, S. W. L., Paoletti, C., Campisi, M., Osaki, T., Adriani, G., Kamm, R. D., Mattu, C., & Chiono, V. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.007 · Cited by 437
Surface-Engineered Dendrimers in Gene Delivery
Yang, J., Zhang, Q., Chang, H., & Cheng, Y. (2015) · Chemical Reviews · doi:10.1021/cr500542t · Cited by 429
Review of polysaccharide particle-based functional drug delivery
Barclay, T. G., Day, C. M., Petrovsky, N., & Garg, S. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.05.067 · Cited by 396
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
“Table 3 lists some examples of multifunctional nanoparticle formulations to facilitate gene and anticancer drug combination [99-107].”
BackgroundInfluentialSynthesis, Bioapplications, and Toxicity Evaluation of Chitosan-Based Nanoparticles
Rizeq, B. R., Younes, N. N., Rasool, K., & Nasrallah, G. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225776 · Cited by 358
Recent advances in natural polymer-based drug delivery systems
Tong, X., Pan, W., Su, T., Zhang, M., Dong, W., & Qi, X. (2020) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2020.104501 · Cited by 349
Non-coding RNAs and potential therapeutic targeting in cancer
Toden, S., Zumwalt, T. J., & Goel, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188491 · Cited by 327
Combinational strategy for high-performance cancer chemotherapy
Qin, S.-Y., Cheng, Y.-J., Lei, Q., Zhang, A.-Q., & Zhang, X.-Z. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.027 · Cited by 301
miRNA nanotherapeutics for cancer
Ganju, A., Khan, S., Hafeez, B. B., Behrman, S. W., Yallapu, M. M., Chauhan, S. C., & Jaggi, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.014 · Cited by 298
Zhong, Y., Goltsche, K., Cheng, L., Xie, F., Meng, F., Deng, C., Zhong, Z., & Haag, R. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.049 · Cited by 290
Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2017.11.003 · Cited by 288
Chitosan-based Colloidal Polyelectrolyte Complexes for Drug Delivery: A Review
Wu, D., Zhu, L., Li, Y., Zhang, X., Xu, S., Yang, G., & Delair, T. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116126 · Cited by 288
Nanoparticle-mediated targeted drug delivery for breast cancer treatment
Liyanage, P. Y., Hettiarachchi, S. D., Zhou, Y., Ouhtit, A., Seven, E. S., Oztan, C. Y., Celik, E., & Leblanc, R. M. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.006 · Cited by 287
Hyaluronic acid and its derivatives in drug delivery and imaging: Recent advances and challenges
Tripodo, G., Trapani, A., Torre, M. L., Giammona, G., Trapani, G., & Mandracchia, D. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.032 · Cited by 286
Kalla, R., Ventham, N. T., Kennedy, N. A., Quintana, J. F., Nimmo, E. R., Buck, A. H., & Satsangi, J. (2015) · Gut · doi:10.1136/gutjnl-2014-307891 · Cited by 267
Recent advances in the medical applications of hemostatic materials
Guo, Y., Wang, M., Liu, Q., Liu, G., Wang, S., & Li, J. (2023) · Theranostics · doi:10.7150/thno.79639 · Cited by 249
“These can also function as drug delivery vehicles to realize the precise release of antitumor drugs [226] and insulin [227] to target areas.”
BackgroundTherapeutic targeting of non-coding RNAs in cancer
Slaby, O., Laga, R., & Sedlacek, O. (2017) · Biochemical Journal · doi:10.1042/bcj20170079 · Cited by 248
Phytochemical delivery through nanocarriers: a review
Ahmad, R., Srivastava, S., Ghosh, S., & Khare, S. K. (2021) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2020.111389 · Cited by 214
Hatmal, M. M., Alshaer, W., Al-Hatamleh, M. A. I., Hatmal, M., Smadi, O., Taha, M. O., Oweida, A. J., Boer, J. C., Mohamud, R., & Plebanski, M. (2020) · Cells · doi:10.3390/cells9122638 · Cited by 196
“The amino acids that interact at the ACE2 and SARS-CoV-2 receptor-binding domain (RBD) interface have been analyzed through the crystal structure (PDB IDs: 6LZG and 6M17) [2,9,10].”
Targeting microRNAs as key modulators of tumor immune response
Paladini, L., Fabris, L., Bottai, G., Raschioni, C., Calin, G. A., & Santarpia, L. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0375-2 · Cited by 184
“Polymeric micelles, polymeric nanoparticles and carbon nanomaterials have already been employed in co-delivery system of different miRNAs and chemotherapeutics in different tumor models [189–192].”
Concepts for Developing Physical Gels of Chitosan and of Chitosan Derivatives
Sacco, P., Furlani, F., De Marzo, G., Marsich, E., Paoletti, S., & Donati, I. (2018) · Gels · doi:10.3390/gels4030067 · Cited by 168
“developed chitosan-hyaluronan nano-gels suitable to overcome drug resistance in breast cancer [84].”
BackgroundThe comprehensive landscape of miR-34a in cancer research
Li, S., Wei, X., He, J., Cao, Q., Du, D., Zhan, X., Zeng, Y., Yuan, S., & Sun, L. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09973-3 · Cited by 84
Self-citationNanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Tirella, A., Kloc-Muniak, K., Good, L., Ridden, J., Ashford, M., Puri, S., & Tirelli, N. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.032 · Cited by 60
Yin, T., Liu, Y., Yang, M., Wang, L., Zhou, J., & Huo, M. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b19373 · Cited by 37
Mokri, N., Sepehri, Z., Faninam, F., Khaleghi, S., Kazemi, N. M., & Hashemi, M. (2022) · Gene Therapy · doi:10.1038/s41434-021-00265-7 · Cited by 36
Zhang, R., Wang, S.-B., Wu, W.-G., Kankala, R. K., Chen, A.-Z., Liu, Y.-G., & Fan, J.-Q. (2017) · Journal of Nanoparticle Research · doi:10.1007/s11051-017-3913-8 · Cited by 22
“This interferes with the stabilization of Bcl-2 mRNA by nucleolin and may be one mechanism bywhich AS1411 induces tumor cell death (Deng et al. 2014).”
Background
Metadata
- Authors
- Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y., & Zeng, Y.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 35
- Issue
- 14
- Pages
- 4333-4344
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2010693773
- Cited by
- 511
- References
- 45
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.